Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Alecensaro | alectinib | ALK-positive NSCLC | Received | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Received | |||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending |
Last Updated : May 4, 2024